Home SPRO
2.0315
  Price1.93%   -0.0385
 
loading
Calls Options of SPRO for (Expired in 13 days)
Strike Price Change % Change Volume
favorite 1.00 1.30 0.00 0.00% 0
favorite 2.50 0.10 0.00 0.00% 10
favorite 4.00 0.05 0.00 0.00% 0
favorite 5.00 0.05 0.00 0.00% 0
favorite 6.00 0.05 0.00 0.00% 0
favorite 7.50 0.01 0.00 0.00% 0
favorite 10.00 0.05 0.00 0.00% 0
favorite 12.50 0.05 0.00 0.00% 0
favorite 15.00 0.55 0.00 0.00% 0
favorite 17.50 0.00 0.00 0.00% 0
favorite 20.00 0.22 0.00 0.00% 0
Puts Options of SPRO for (Expired in 13 days)
Strike Price Change % Change Volume
favorite
1.00
0.05 0.02 +66.67% 5
favorite
2.50
0.55 0.05 +10.00% 11
favorite
4.00
2.00 0.00 0.00% 0
favorite
5.00
3.10 0.00 0.00% 0
favorite
6.00
0.00 0.00 0.00% 0
favorite
7.50
0.00 0.00 0.00% 0
favorite
10.00
5.40 0.00 0.00% 0
favorite
12.50
0.00 0.00 0.00% 0
favorite
15.00
0.00 0.00 0.00% 0
favorite
17.50
0.00 0.00 0.00% 0
favorite
20.00
0.00 0.00 0.00% 0
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting. The company also develops SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; SPR720, an oral antibiotic, which is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Cap:    |  Volume (24h):